- Home
- BDTX vs KLRS Comparison
BDTX vs KLRS Comparison
Compare BDTX & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BDTX | KLRS |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 132.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | BDTX | KLRS |
|---|---|---|
| Price | $2.67 | $5.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $9.50 | ★ $20.67 |
| AVG Volume (30 Days) | ★ 579.2K | 63.1K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 130.71 | N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.97 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $2.14 |
| 52 Week High | $4.94 | $11.88 |
Technical Indicators
Market Signals| Indicator | BDTX | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 64.71 | 35.64 |
| Support Level | $2.45 | $4.35 |
| Resistance Level | $2.86 | $7.20 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | 0.06 | 0.11 |
| Stochastic Oscillator | 88.00 | 29.47 |
Price Performance
Historical ComparisonAbout BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.